A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema

Exclusion Criteria

• •Hemoglobin A1c (HbA1c) of greater than (\>) 12%
• •Uncontrolled blood pressure, defined as a systolic value greater than (\>)180 millimeters of mercury (mmHg) and/or a diastolic value \>100 mmHg while a patient is at rest
• •Currently pregnant or breastfeeding, or intend to become pregnant during the study
• •Prior treatment with panretinal photocoagulation or macular laser to the study eye
• •Any intraocular or periocular corticosteroid treatment within the past 16 weeks prior to Day 1 to the study eye
• •Prior Iluvien or Retisert implants within 3 years prior to Day 1 to the study eye
• •Prior or concomitant treatment with anti-VEGF therapy within 8 weeks prior to Day 1 to the study eye; Vabysmo\^TM within 16 weeks prior to Day 1, prior Beovu® is not permitted
• •Prior administration of IVT brolucizumab (Beovu®): ever; vamikibart: \</=24 weeks prior to Day 1) in either eye
• •Any proliferative diabetic retinopathy
• •Active intraocular or periocular infection or active intraocular inflammation in the study eye
• •Any current or history of ocular disease other than DME that may confound assessment of the macula or affect central vision in the study eye
• •Any current ocular condition which, in the opinion of the investigator, is currently causing or could be expected to contribute to irreversible vision loss due to a cause other than DME in the study eye